A 64-year-old man was cured of his lifelong type 1 diabetes after receiving an investigational treatment that turns stems cells into insulin-secreting islet cells, as part of a clinical trial led by Vertex Pharmaceuticals. (New York Times)
A new review in The Lancet Diabetes & Endocrinology is offering guidance to healthcare professionals working with patients using do-it-yourself automated insulin-delivery systems.
After struggling with infertility for over a decade, a North Carolina woman welcomed her first child at age 50, all thanks to IVF. (CBS News)
Babies given juice earlier on as infants were subsequently more likely to drink soda and were less likely to opt for water as children. Some factors tied to earlier juice introduction included younger moms, lower socioeconomic status, and Black or Hispanic race or ethnicity. (The Journal of Nutrition)
Founded back in 1981, The Obesity Society is celebrating its 40th birthday. “The events leading up to its founding and its early history have been recounted by two of the founders and the first president in the current issue of Obesity,” said past-president George A. Bray, MD, in a statement.
The U.S. House of Representatives recently voted to approve an almost $2 trillion social and climate spending package — which includes a $35 cap on monthly insulin expenses. Praising this move, Endocrine Society President Carol H. Wysham, MD, said in a statement: “People with diabetes cannot wait any longer for Congress to take action. We urge the Senate to quickly follow suit.” (NPR)
Cone snail venom: the next frontier in diabetes treatments? (ScienceDaily)
Medtronic Chair & CEO Geoff Martha said the company is “making progress with the FDA” to get a green light for its next-generation MiniMed 780G insulin pump system with the Guardian 4 sensor for continuous glucose monitoring. (Drug Delivery Business News)
Canadian psychedelic medicine biotech company Clearmind announced a partnership with the Hebrew University of Jerusalem’s Obesity and Metabolism Laboratory to test one of its investigational 5-methoxy-2-aminoindane (MEAI) compounds (a recreational drug often used as a binge drinking preventative) on binge eating, plus the effect on physical activity and metabolic parameters. (Yahoo! Finance)
Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.